drug · antibody
blinatumomab
Marketedupdated 5mo agoby $AMGN AMGEN INC🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4Antibody drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 12 investigational indications.
targets
B-lymphocyte antigen CD19T cell surface glycoprotein CD3
all catalysts(25)
approval · 23
Dec 3, 2014
approval
$AMGN414.87+1.82%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Aug 30, 2016
approval
$AMGN414.87+1.82%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Aug 30, 2016
approval
$AMGN414.87+1.82%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
May 3, 2017
approval
$AMGN414.87+1.82%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Jul 11, 2017
approval
$AMGN414.87+1.82%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Nov 30, 2017
approval
$AMGN414.87+1.82%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Mar 29, 2018
approval
$AMGN414.87+1.82%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Apr 10, 2018
approval
$AMGN414.87+1.82%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Apr 18, 2019
approval
$AMGN414.87+1.82%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Apr 18, 2019
approval
$AMGN414.87+1.82%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Mar 20, 2020
approval
$AMGN414.87+1.82%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Mar 11, 2021
approval
$AMGN414.87+1.82%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Mar 11, 2021
approval
$AMGN414.87+1.82%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Mar 11, 2021
approval
$AMGN414.87+1.82%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Feb 18, 2022
approval
$AMGN414.87+1.82%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Dec 5, 2022
approval
$AMGN414.87+1.82%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Jun 20, 2023
approval
$AMGN414.87+1.82%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Jun 20, 2023
approval
$AMGN414.87+1.82%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Feb 8, 2024
approval
$AMGN414.87+1.82%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Jun 14, 2024
approval
$AMGN414.87+1.82%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Dec 17, 2024
approval
$AMGN414.87+1.82%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Apr 29, 2025
approval
$AMGN414.87+1.82%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Oct 21, 2025
approval
$AMGN414.87+1.82%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
phase 1 2 completion · 1
Trials studying blinatumomab
- phase2A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
- phase2A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
- phase2Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- phase3A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia
- phase2Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
- phase3A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
- phase2A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
- phase2A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
News(2)
- Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s AbogenNovartis is licensing an mRNA-based therapy designed to produce a CD3xCD19 T cell engager inside the body. Abogen Biosciences says the in vivo approach could reduce the likelihood of dangerous cyto…biospace · 8d ago
- Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engagerNovartis is paying Abogen Biosciences $575 million upfront for an mRNA-encoded T-cell engager that showed early clinical promise in autoimmune disease. The deal, which includes up to $7.2 billion i…fiercebiotech · 9d ago
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that